Radiodermatitis Market Size To Reach $557.1 Million By 2030

Radiodermatitis Market Growth & Trends

The global radiodermatitis market size is expected to reach USD 557.1 million by 2030, and market is projected to grow at a CAGR of 4.0% from 2025 to 2030, according to a new report by Grand View Research, Inc.. The rising global incidence of cancer is a key factor driving the market growth. As cancer rates increase, more patients are receiving radiation therapy as part of their treatment plans. In February 2024, the WHO reported that around 20% of individuals are expected to be diagnosed with cancer at some point in their lives, with roughly 1 in 9 men and 1 in 12 women succumbing to the illness, resulting in a growing need for effective solutions to manage side effects like radiodermatitis. This condition, marked by skin irritation and damage from radiation exposure, calls for specialized treatments focused on alleviating symptoms and promoting healing. Consequently, pharmaceutical and medical device companies prioritize developing innovative therapies and products to address the radiodermatitis industry.

The growing awareness and emphasis on patient care during cancer treatment play a significant role in improving outcomes. Healthcare providers are increasingly acknowledging the need to address side effects related to radiation therapy, such as radiodermatitis. The May 2024 review in Bioengineering & Translational Medicine highlighted the clinical use of hydrogels since the late 1980s across drug delivery, cosmetics, and tissue regeneration. Recent advancements in polymer chemistry and fabrication have resulted in over 100 FDA and EMA-approved hydrogel products derived from natural, synthetic, or combined materials. These products serve various purposes, including tissue regeneration, facial correction, wound dressing, and drug delivery, and include both injectable and non-injectable options in clinical trials.

 Request a free sample copy or view report summary: Radiodermatitis Market Report

Radiodermatitis Market Report Highlights

• The topical products segment dominated in 2024 with a market share of 71.7%, primarily due to their easy accessibility, enhanced convenience, and advantages over oral alternatives. These products are expected to experience significant growth thanks to their diverse formulations, including creams, gels, and ointments tailored to meet patient needs.

• In terms of distribution channel, the retail pharmacies segment accounted for a substantial share of 39.4% in 2024 owing to the rising number of pharmacies. Retail pharmacies capture a large percentage of prescriptions written in the hospital. 

• Europe dominated the market globally with a market share of 34.0% due to advanced healthcare infrastructure, high awareness of skin care treatments, and a large patient population undergoing radiation therapy.

• North America accounted for the second-largest market share due to significant R&D initiatives that have created promising growth opportunities. Advanced therapeutic products in the region are a key factor contributing to its growth in the radiodermatitis industry.

• The competition features key players implementing strategies like product launches, distribution agreements, and strategic partnerships, which have greatly expanded their market share.

Radiodermatitis Market Segmentation

Grand View Research has segmented the global radiodermatitis market based on product, distribution channel, and region:

Radiodermatitis Product Outlook (Revenue, USD Million, 2018 - 2030)

• Topical

  • Corticosteroids

  • Hydrophilic Creams

  • Antibiotics

  • Others

• Dressings

  • Hydrogel & Hydrocolloid Dressings

  • No Sting Barrier Film

  • Honey-impregnated Gauze

  • Silicone-coated Dressings

  • Others

Radiodermatitis Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)

• Hospital Pharmacies

• Retail Pharmacies

• Online Pharmacies

Radiodermatitis Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • South Korea

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East & Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in the Radiodermatitis Market

• Stratpharma AG

• Smith & Nephew

• Molnlycke Health Care AB

• Derma Sciences Inc.

• ConvaTec Inc.

• BMG Pharma S.R.L.

• Acelity (3M)

• Alliqua BioMedical